Insulin Market in Europe 2015-2019
Insulin is a hormone produced by the beta cells of the pancreas; insulin has a key role in regulating the blood glucose levels. It regulates the metabolism of glucose and other nutrients in the body. Insulin permits the body to utilize sugar (glucose) from carbohydrates in the food for energy or to store glucose for future use. The beta cells of the pancreas of people with type 1 diabetes do not produce sufficient insulin to regulate blood glucose level; therefore, they need to intake insulin daily. On the other hand, people with type 2 diabetes or gestational diabetes need doses of insulin together with other medication. Different type of insulin such as human insulin and insulin analogs are available for insulin replacement therapy.
Technavio's analysts forecast the insulin market in Europe to grow at a CAGR of 6.50% over the period 2014-2019.
Covered in this report
The report covers the present scenario and the growth prospects of the insulin market in Europe for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various insulin used for the treatment of diabetes.
Technavio's report, Insulin Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the insulin market in Europe and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Insulin Market in Europe 2015-2019
Technavio recognizes the following companies as the key players in the Insulin Market in Europe: Eli Lilly and Co., Novo Nordisk A/S and Sanofi SA
Other Prominent Vendors in the market are: Biodel, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals, Macrogenics, Merck, Osiris Therapeutics, Tolerion and XOMA
Commenting on the report, an analyst from Technavio’s team said: “Growing public awareness of diabetes and the available treatments will likely increase the number of people opting for these treatments. Healthcare companies are organizing awareness camps and discussions to educate people about the condition. These are conducted either alone or in combination with other national institutes.”
According to the report, changing lifestyle, consumption of high-fat-containing foods, and reduced physical activity increase the prevalence of obesity among the population. Obesity affects the body's normal metabolism, triggering the adipose tissues to release increased amounts of fatty acids, hormones, pro-inflammatory cytokines, and other factors, which are involved in insulin resistance.
Further, the report states that the development and regulatory approval of biologic insulin and insulin analog products take longer than small molecules. Minor alterations in the physical structure and chemical pattern can significantly alter the safety and efficacy of these moieties. Unnoticeable variations in the design and execution of a manufacturing process can alter the pharmacokinetic and pharmacodynamics profiles of a drug.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook